Relax Biotech Private Limited - Due diligence report

A 360° intelligence report on Relax Biotech: trust score, financial health, credit view, compliance, directors, growth and distress signals …

2012-06-01 Vadodara, Gujarat Active Unlisted Active Compliant
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Relax Biotech — 360° Intelligence Report

Generated from MCA filings & public records
79/100
Trust Score
Low Risk

Relax Biotech is assessed as Low Risk with a Trust Score of 79/100. Relax Biotech is an active private limited indian non-government company incorporated in 2012, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 22 Nov 2026 from the latest processed filings. Relax Biotech Private Limited snapshot & full profile →

Overall Assessment CautionWeakNeutralGoodStrong Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
79/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
68/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 0 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open ( 48.0 cr ) · 3 satisfied ( 12.5 cr ).

Banking relationships (from registered charges)
LenderChargesAmount
Others2 48.0 cr
Yes Bank Limited2 48.0 cr
Central Bank Of India1 48.0 cr
Compliance Score: 68/100 Moderate
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2024 - filings overdue.
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
JIGNESHBHAI UTTAMBHAI PATEL 01234567 Director 01/04/2018 6 yrs Approved
DEVANG KAUSHIKBHAI SHAH 01234567 Director 01/04/2018 6 yrs Approved
NILESHKUMAR UTTAMBHAI PATEL 01234567 Director 01/04/2018 6 yrs Approved
BHAVIN BECHARBHAI MANGROLIA 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 3 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 14+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Statutory filings appear overdue.
2 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) already registered.
  • Compliance gaps should be priced into terms.
Investor view78/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
13 Mar 2023
Charge created
Others - 9.99 cr
07 Mar 2023
Charge created
Others - 9.99 cr
14 Feb 2023
Charge satisfied
Yes Bank Limited
31 Mar 2022
Share transfer (FY 2022)
153018.00000000 shares to Devang Kaushikbhai Shah
Share transfer (FY 2022)
903017.00000000 shares to Bhavin Becharbhai Mangrolia
Share transfer (FY 2022)
209595.00000000 shares to Devang Kaushikbai Shah
02 Dec 2021
Director ceased
NIMESHKUMAR GOVINDBHAI PATEL
18 Nov 2019
Director ceased
PRITESH JASHBHAI PATEL
30 Sep 2018
Director ceased
DEVANG KAUSHIKBHAI SHAH
Director ceased
HIRENKUMAR VINODCHANDRA SHAH
Director ceased
BHAVIN BECHARBHAI MANGROLIA
18 Sep 2018
Charge created
Yes Bank Limited - 5.00 cr
09 Aug 2018
Charge satisfied
Central Bank Of India
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
Approximately 19 employees on EPFO payroll records.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Biograde Organics Private Limited U24110PB2020PTC050663 Ludhiana, Punjab, India
Coroseal Chemical Equipments Private Limited U29290MH1997PTC110317 Navi Mumbai, Maharashtra, India
Millennium Herbal U24230MH2000PLC124714 Mumbai, Maharashtra, India
Olive Lifesciences U24230KA2007PTC043892 Bangalore, Karnataka, India
Spen Formulations Pvt Ltd U45202HP2006PTC030153 H P, Himachal Pradesh, India
Glamac International Private Limited U74999MH2017PTC295512 Thane, Maharashtra, India
Sujal Dyechem Private Limited U24100GJ2008PTC054388 Ahmedabad, Gujarat, India
Radix Chemicals Private Limited U24245GJ2012PTC072745 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Relax Biotech before audits and certifications: compliance score 68/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Relax Biotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Relax Biotech - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 79/100, distress signals and MSME payment-delay disclosures - know whether Relax Biotech pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Relax Biotech - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Relax Biotech an active company?

Relax Biotech has MCA status “Active” with a compliance score of 68/100 (Moderate).

Is Relax Biotech financially healthy?

Relax Biotech has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Relax Biotech?

Its overall Trust Score is 79/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Relax Biotech?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Relax Biotech have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Relax Biotech up to date with its ROC filings?

Last balance sheet is for Mar 2024 - filings overdue. Overall compliance score: 68/100 (Moderate).

Is it risky to lend to Relax Biotech?

Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.